Clinical Trial

A Study of Intravenous CPTX2309 in Healthy Participants and Participants With Moderate to Severe Rheumatoid Arthritis (RA) or Systemic Lupus Erythematosus (SLE)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and tolerability of CPTX2309 in healthy adult participants and adult participants with moderate to severe rheumatoid arthritis or systemic lupus erythematosus.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-04-02; most recent amendment 2026-07-14.
Status change: Not Yet Recruiting → Recruiting 2025-04-08
Trial Details
NCT Number NCT06917742
Lead Sponsor Capstan Therapeutics
Conditions Healthy Volunteers, Rheumatoid Arthritis, Systemic Lupus Erythematosus
Enrollment 64 participants
Start Date 2025-04-09
Primary Completion 2027-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-07-16